NewsRoom Articles - Page 156 of 207

MondayMay 10, 2021 12:06 pm

Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Looks to New Senior Management with Expertise in Development, Clinical Capabilities

Company committed to building presence in U.S. and Europe to advance mission of improving mental health care New appointments will strengthen Cybin’s development and clinical operations globally, solidify position within the industry New leaders bring broad experience, deep insight to their new roles Cybin (NEO: CYBN) (OTCQB: CLXPF), a leading biotech company focused on progressing psychedelic therapeutics, recently made key senior-management changes designed to provide the company with added insight and expertise in the expansion of its development and clinical operations in the United States and Europe (https://ibn.fm/FsF0L). The appointments, which are effective immediately, call for Alexander Belser, PhD, to…

FridayMay 07, 2021 2:20 pm

Brain Scientific Inc. (BRSF) Featured in Science and Technology Publication as Company Shaping the Future of Neurology Research

Brain Scientific was featured in Neoscope, a publication of Futurism, a media company concentrating on the scientific and technological advances for the future Article details e-tattoo, BRSF’s solution that can capture big data in real-time about brain activity with possible applications in epileptic seizure predictions E-tattoo could prove invaluable to medical researchers studying neurological conditions or even developers building brain-computer interfaces for mind-controlled electronics, video games Brain Scientific (OTCQB: BRSF), a commercial-stage medical device and software company focused on neurology, has been featured in Neoscope as a company that champions cutting-edge research pushing the boundaries of what is possible in…

FridayMay 07, 2021 1:46 pm

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Investigates Alleviating Neurological Disorders with Psychedelics

Tryp Therapeutics is a pharmaceutical developer working to produce novel bioscience solutions, including a synthetic psychedelic drug candidate for treating some chronic pain and eating disorders Tryp CEO Greg McKee appeared on the Entrepreneur Magazine podcast “Action and Ambition” earlier this month to discuss lessons learned on his road to success and to highlight the company’s purpose in developing treatments for helping people be more whole Psychedelic drug therapies have been developing a growing fanbase, highlighted by California state Sen. Scott Wiener’s legislation this year seeking to decriminalize hallucinogenics McKee noted that many military personnel are using psychedelics in an…

FridayMay 07, 2021 12:15 pm

Researchers Propose That Existing Drugs May Help Treat COVID-19

It can take anywhere between a few years to several decades for researchers to develop drugs for various illnesses. However, time is not a luxury that has been afforded to researchers working on therapies to treat patients suffering from the coronavirus. This is why researchers from Northeastern University, in collaboration with Harvard University researchers, devised another way to find treatments for this fatal disease by analyzing treatments already in existence. The group of researchers have published their findings in the “Proceedings of the National Academy of Sciences.” The researchers analyzed all treatments currently available to patients for the treatment of…

ThursdayMay 06, 2021 11:02 am

Researchers Find Possible Cause of Silent Hypoxia in Coronavirus Patients

Researchers still don’t know a lot about the novel coronavirus and how it attacks various organs in the body. However, among the biggest mysteries of this disease is how it causes oxygen levels in an individual’s body to become abnormally low. This condition, usually referred to as silent hypoxia, irreversibly damages an individual’s vital organs if it remains undetected for an extended period of time. With the help of computer models, biomedical engineers from Boston University have begun to get to the bottom of this mystery. Their study, which was reported in the “Nature Communications” journal, was conducted in collaboration…

ThursdayMay 06, 2021 10:45 am

Brain Scientific Inc. (BRSF) Eyes Plans for 2021 and Beyond

Commercial application of NeuroEEG and NeuroCap growing across ICUs, acute inpatient care and other emergency care in U.S. BRSF plans to launch devices in Canada Company expands footprint, plans patent applications in Latin America, Europe Brain Scientific (OTCQB: BRSF), a neurology-focused medical device and software company, has unveiled the outlook for 2021. Brain Scientific continues to make strides within neurology by revolutionizing the brain diagnostic market with its groundbreaking technology. The company recently announced that its R&D efforts surged in 2020 with an investment of $275,926, which marks a 266% increase over 2019’s total of $103,616 (https://ibn.fm/Uiqs7). Despite a challenging…

WednesdayMay 05, 2021 2:50 pm

Researchers Find Young People Can Get Re-infected by the Coronavirus

In most cases, when an individual gets infected with a disease, their body creates antibodies to protect them from the infection were it to occur again. However, researchers have discovered that while SARS-CoV-2 antibodies are protective, they don’t protect young individuals against reinfection. This can be observed in the findings of a longitudinal study that was conducted by scientists from the Naval Medical Research Center and the Icahn School of Medicine at Mount Sinai. The study’s results were reported in “The Lancet Respiratory Medicine Journal.” The senior author of the study, Stuart Sealfon, stated that the findings indicate that SARS-CoV-2…

WednesdayMay 05, 2021 12:03 pm

Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Signs Drug-Development Agreement, One Step Closer to Effective Psychiatric Disorder Treatment

Agreement calls for Cybin, Catalent to work together to develop novel therapy for treatment-resistant psychiatric disorders Cybin looking to identify fast-acting, shorter-duration formulations of CYB003 Delivering CYB003 through Catalent ODT could provide significant benefits Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, has inked a drug-development agreement with Catalent Inc. (NYSE: CTLT), a leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products (https://ibn.fm/nQdpg). The agreement, which is scheduled to start this month, calls for the two companies to work together to potentially…

TuesdayMay 04, 2021 2:24 pm

XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Inks Distribution Agreement for Rapid COVID-19 Test Kits; Expands Commercial Leadership Team in Anticipation of Strong, Sustainable Sales

XPhyto Therapeutics Corp. recently announced it has entered into a distribution, storage and logistics agreement with a German distributor with an established network throughout Germany Germany holds promise due to regulations requiring mandatory weekly testing for its citizens; this has the possibility of ramping up sales Anticipating the increase in sales and distribution, XPhyto expanded its commercial leadership team by bringing on board Mr. Wolfgang Probst and Mr. Manfred Buchberger Mr. Probst will be the company’s Chief Operations Officer (“COO”), while Mr. Buchberger will be the Head of Corporate Development at wholly owned subsidiary XP Diagnostics GmbH The approvals XPhyto…

TuesdayMay 04, 2021 1:48 pm

Computer Analysis May Help Create Personalized Healthy Diets

A mathematical model developed by scientists from Sweden’s Chalmers University of Technology has been designed to help researchers create tailored diets and new probiotics to prevent illnesses. The lead author of the study, Prof. Jens Nielsen, explained that intestinal bacteria played a crucial role in the development of illnesses and the quality of an individual’s health and noted that the mathematical model would be very helpful in these areas. The study was reported in the “PNAS” journal. The new study highlights the performance of the mathematical model in making predictions associated with a couple of prior clinical studies: one that…